Online citations, reference lists, and bibliographies.

The Significance Of Incidental Brain Uptake On 68Ga-DOTATATE PET-CT In Neuroendocrine Tumour Patients

J. Cleary, Jason Yeung, Helena McMeekin, T. Wilhelm, T. Wagner
Published 2016 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
ObjectiveRadiolabelled somatostatin analogues detect neuroendocrine tumours (NETs), but may reveal other tumour types. We examined the prevalence of possible meningioma in patients with known or suspected NETs imaged with 68Ga-DOTATATE PET-computed tomography (CT) on the basis of central nervous system uptake and compared with findings on magnetic resonance and contrast-enhanced CT imaging. MethodsRetrospective imaging reports from 313 patients who had undergone 68Ga-DOTATATE PET imaging for primary or repeat NET staging were searched to identify suspected meningiomas on PET. Images were then compared with findings on subsequent complementary MRI or contrast-enhanced CT scanning (performed within mean±112 days of PET-CT) if available. ResultsOf 313 patients, 22 had regions of uptake suggestive of meningioma. MRI was available for 12 patients and contrast-enhanced CT was available for one patient. Of these, one patient with known von Hippel-Lindau syndrome had probable cerebellar NET metastasis. Six patient scans indicated lesions consistent with PET. Two of these reported initially did not comment on meningioma. No obvious lesion was found in the remaining six patients; however, five showed a possible correlation to venous structures. The mean maximum standardized uptake value±SEM for lesions in all 21 probable meningioma patients was 4.90±0.45. Conclusion68Ga-DOTATATE is a sensitive marker of probable meningioma and may identify small lesions not reported on subsequent MRI. Lesions clearly observed on PET were identified on review in half of patients where complementary MR or CT imaging was available. Haemangioblastoma and metastatic NETs may have focal peripheral uptake similar to meningioma on 68Ga-DOTATATE PET and should be considered in the differential.
This paper references
Radiological diagnostics of meningiomas
M. Batra (2015)
10.1056/NEJMOA070972
Incidental findings on brain MRI in the general population.
Meike W. Vernooij (2007)
10.1007/s11060-010-0386-3
Epidemiology and etiology of meningioma
Joseph Wiemels (2010)
cerebellar disease
R Hlatky (2011)
10.3171/jns.2006.105.2.256
Metastases to hemangioblastomas in von Hippel-Lindau disease.
S. Taylor Jarrell (2006)
tumor-free tissue
A Afshar-Oromieh (2015)
Somatostatin receptorbased PET/CT of intracranial tumors: a potential area of application for 68Ga-DOTA peptides
P Sharma (2013)
10.1007/978-1-60327-161-5_194
[Von Hippel-Lindau disease].
K. Takahashi (2006)
10.1148/rg.352140164
Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation.
Michael S. Hofman (2015)
PETand PET/CT with 68gallium-labeled somatostatin analogues in non GEPNETs Tumors
M Sollini (2014)
10.2967/jnumed.114.149120
Increased 68Ga-DOTATATE Uptake in PET Imaging Discriminates Meningioma and Tumor-Free Tissue
Walter Rachinger (2015)
10.1016/j.ijrobp.2010.10.078
Simultaneous 68Ga-DOTATOC-PET/MRI for IMRT treatment planning for meningioma: first experience.
Daniela Thorwarth (2011)
10.1097/MNM.0b013e32833f635e
Distribution pattern of 68Ga-DOTATATE in disease-free patients
Manu Shastry (2010)
10.1093/neuonc/nou223
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.
Quinn T Ostrom (2014)
Somatostatin receptor imaging with 68Ga
MS Hofman (2000)
10.1186/1748-717X-4-56
[68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning
Barbara Gehler (2009)
Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A.
S Schulz (2000)
10.1007/s00259-012-2155-3
Detection of cranial meningiomas: comparison of 68Ga-DOTATOC PET/CT and contrast-enhanced MRI
A. Afshar-Oromieh (2012)
10.1002/cncr.20659
Carcinoid metastasis to the brain.
R. Hlatký (2004)
10.1097/RLU.0b013e3181fef14a
68Ga-DOTA-NOC PET/CT detects somatostatin receptors expression in von hippel-lindau cerebellar disease.
V. Ambrosini (2011)
10.2214/AJR.13.10987
Somatostatin receptor-based PET/CT of intracranial tumors: a potential area of application for 68 Ga-DOTA peptides?
P. Sharma (2013)
10.1007/s00347-012-2702-0
Radiologische Diagnostik von Meningeomen
Marcel Batra (2012)
10.1016/0090-3019(87)90005-X
Incidental meningiomas in autopsy study.
S. Nakasu (1987)
10.1212/WNL.36.6.745
Neurologic complications of carcinoid
Roy A. Patchell (1986)
tumor-free tissue
A Afshar-Oromieh (2015)
10.3171/2011.9.FOCUS11220
Incidental meningiomas.
R. Chamoun (2011)
10.1007/s00259-010-1512-3
Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE
I. Virgolini (2010)
10.1155/2014/194123
PET and PET/CT with 68Gallium-Labeled Somatostatin Analogues in Non GEP-NETs Tumors
Martina Sollini (2014)
Somatostatin receptor
P Sharma (2013)
10.1007/s12149-013-0718-4
Physiological and tumoral uptake of 68Ga-DOTATATE: standardized uptake values and challenges in interpretation
Serkan Kuyumcu (2013)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar